The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I donât think any biotech is going to keep updating the market with negative news like:
We had discusssions with parties it didnât work out
We had discussions with government it didnât work out
We failed to get on x, y or z trial.
It doesnât help the share price and doesnât help the investors confidence either.
People had the opportunity at various AGMs to ask these types of questions and many who complain here never attended.
The board provided a broad overview of the issues in their interim report and it really doesnât take rocket science to see how the changing landscape of the virus, vaccines and funding has impacted us.
The boards interim report:
âOver the course of 2022, as the burden on hospitals from COVID-19 has receded, large platform trials likewise have wound down due to low infection rates and changes in funding or have evolved to focus on more specific aspects of COVID-19. We have engaged and continue to engage with many of these platform trial sponsors in the US, Europe and the UK, and remain ready to participate in suitable platform trialsâ
What we need is not hand holding but delivery of the trials. Iâd love that to have been last year or even next month but it will happen when all the pieces are in place and until that time everyone needs to be patient.
Just like our biggest investors are being.
Spacman
Youâre clearly not going to tell us what this alternative/ mitigating strategy is that the board should have had in place. Iâm guessing itâs because itâs another of your broad brush themes that lacks detail but sounds good for the click bait likes you get.
Youâre not going to tell us what the board should have done immediately after the trial failure other than approach BP for a sale. I think most of us think thatâs a rather unbelievable strategy and certainly had they done it, wouldnât have recouped your 97% loss or anyone elseâs.
Is the company worth 500m now? I very much doubt it until the board have followed through on their plans and after that I have no idea, because the company might be sold or the company might license their drug either in whole or part to different BP depending on trials results, competition amongst interested parties etc.
Youâre an interesting character who clearly has a level of knowledge but chooses to use it to play with this board. Iâm not sure if thatâs a trading strategy or you do it just for the fun of it.
But your theories are wild, amusing and generally when you dig deeper, somewhat implausible.
No doubt youâll be back next week for another fun packed post
Well that was fascinating if somewhat less informative than I had hoped.
So many questions around this mitigation?
Not sure how the share could go to ÂŁ2 if the board reached out for a sale, unless they somehow broke trading rules and told everyone what they were doing but maybe that can be explained to us?
Interesting view on what a P2 company is worth but we donât have a successful P2. We have some interesting data that needs further work to entice a partner.
It sounds like a lot of jumbled up logic that when you do the analysis doesnât stand up to the scrutiny.
fwiw In my view the company have the right approach which is to prove we can identify our patient group and then discuss with a partner a p3 or sale. Those are the obvious choices. What thatâs worth is a rather futile exercise. We might as well just wait for the data and then see.
Itâs clear that anyone buying at these prices should the trials succeed will make a great return and good to them and all of us.
Spacman
What was the alternative strategy / mitigation.?
Iâm still not clear at the point the trial failed and the share price collapsed. Are you saying the board should have put the for sale sign up and sold the company for what?
Assuming you lost 97% of your investment are you saying the company was 500m then or now?
If it was wasnât worth 500m at the point of failure but is now that would suggest the board have actually done a Stirling job ?
Perhaps you can clarify?
Interesting Spacman
So at the point of failure they should have reached out to BP to buy the company and at what price?
I assuming given you keep mentioning the 97% drop in your investment the price you are going to tell us theyâd have got after Sprinter failed youâd have voted for?
Ok Spacman
Weâre getting somewhere. So the drop in the share was unavoidable so I assume you keep mentioning it because you bet on a drug it failed and now youâre bitter that it was t 100 guaranteed to succeed.
So letâs move on so 2 years ?
So tell us what they should have done in the 2 years that they didnât do and you would have done?
Iâm sure weâd all like the benefit of your knowledge Spacman
So on the fateful day that the share price dropped to 10p following the announcement of the failed trial. What should the board have done to prevent the share falling to 10p.
You always seem to imply there was a way of preventing that fallâŚwhat was it?
Spacman
Reverting to R&D?
Going it alone?
You donât believe half of what you write anymore than I do.
Classic activity on a public chat board to attack the company, its directors, its stated aims and its remuneration.
Your themes and tactics are highly amusing but unconvincing.
2m shares were traded on 29/12
Yesterday 700k
And today 100k
Does this mean the company was 20 times more popular in December than today?
if 500k shares are traded on Monday does that mean the company is 5 times more popular than today?
Or do share volumes just fluctuate whilst waiting the next big event and the availability of volumes to trade?
Thanks to Mr Costs for sharing the plan
Here you are Spacman
âPlan will start with a series of focused, investigator-led/Synairgen-sponsored studies, using existing resources, which are intended to lead towards a Phase 3 registrational programmeâ
So many incorrect interpretations of what the company have said.
So I reread the interim RNS
âSubject to this preparatory work and regulatory approval timelines, trials are âanticipatedâ to start in H1 2024â
It is the Company's goal to commence trials as soon as possible, âsubject toâ approval timelines, and within H1 2024
The company learned a valuable lesson from that AGM
Never anticipate something is going to happen that you donât control, like a Platform Trial because the money evaporated.
Never tie yourself down to exact timeframes until everything is in place
âPost SPRINTER we were lead to believe that many interested parties
were in discusssion with SNG and there was a very real prospect of dosing patientsâ
And thatâs exactly why we do not want a pointless hand holding update saying âWeâre on trackâ
Because until we have signed contracts and agreed dates with trial hospitals, delivered drugs and have regulatory agreements a date itâs not guaranteed.
As WPA pointed out we are 25 days into a 6 month window. Anything could happen in that time to disrupt Synairgenâs plan and an update now would be as useful as the winter trials update at the AGM.
When the company know the patients will be dosed on x date they will tell us.
If the company for any reason isnât going to achieve H1 then they will update the market.
The company have responded to emails and nothing in those emails said Delay